← Leaderboards
Hans-Peter Kiem
Fred Hutchinson Cancer Center
$98,160,227
Attributed
$121,811,861
Total exposure
52
Grants
39
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $15.7M · FY2005–25$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$190,675,653 · 58
By mechanism
U19$68,453,853 · 14
R01$43,769,421 · 15
P01$40,799,238 · 13
UM1$24,161,173 · 1
U01$4,425,306 · 2
RL1$3,077,768 · 1
Top collaborators
- Paula M Cannon12 shared
- Keith R Jerome12 shared
- Shahin Rafii9 shared
- Bruce R. Blazar5 shared
- Scott G Kitchen5 shared
- Nathaniel R. Landau5 shared
- David J Rawlings5 shared
- Roland Bruno Walter5 shared
Most similar at Fred Hutchinson Cancer Center
Same institution · by research overlap
- Roland Bruno Walter$12,142,218
Others in their field
Top investigators on “Hematopoietic Stem Cells”
- Mary M Horowitz · Medical College Of Wisconsin$222,127,419
- David T Scadden · Massachusetts General Hospital$40,987,034
- David A Williams · Indiana Univ-Purdue Univ At Indianapolis$36,503,708
- Irving Lerner Weissman · Stanford University$36,281,548
- Bruce R. Blazar · University Of Minnesota$33,175,355
- Marcel R M Van Den Brink · Sloan-Kettering Institute For Cancer Res$31,152,075
Research focus
Hematopoietic Stem CellsCellsGene TherapyIn VivoBaseTransplantationGenesEngraftmentNonhuman PrimateConditioningSafetyAnimalsToxic EffectRegimenAutologousStem CellsGene-ModifiedMediatingHematopoieticAnimal ModelVectorDoseInfectionProtocols Documentation
Grant awards (200)
In vivo cell engineering for HIV cure.$3,693,667
P01 · FY2025 · HL
In vivo HSC gene therapy using a multi-modular HDAd vector for HIV cure$1,399,750
R01 · FY2025 · AI
Immunoengineering Durable Control of HIV Replication$1,362,935
P01 · FY2025 · HL · contact PI
In vivo hematopoietic stem cell engineering for HIV cure$880,758
P01 · FY2025 · HL · contact PI
CD90-targeted nanoparticles for in vivo hematopoietic stem cell gene therapy$814,209
R01 · FY2025 · HL · contact PI
Microglia replacement using engineered HSCs for treatment of leukodystrophies$694,134
R01 · FY2025 · NS
Novel hematopoietic stem cell engineering and transplantation approaches for HIV cure$2,334,036
U19 · FY2024 · HL
Multiplex base/prime editors for in vivo selection of modified HSPCs in hemoglobinopathy$728,713
R01 · FY2024 · HL · contact PI
In vivo HSC gene therapy using a multi-modular HDAd vector for HIV cure$658,154
R01 · FY2024 · AI
Nongenotoxic conditioning to enhance stem cell engineering and virus-specific immunity in nonhuman primates$468,828
U19 · FY2024 · HL · contact PI
Primate Core$417,909
U19 · FY2024 · HL · contact PI
Cell Manipulation Tools$225,250
U54 · FY2024 · DK · contact PI
Novel hematopoietic stem cell engineering and transplantation approaches for HIV cure$3,528,529
U19 · FY2023 · HL
Primate Core$1,333,524
U19 · FY2023 · HL · contact PI
Nonhuman Primate Core$961,891
U19 · FY2023 · AI · contact PI
Development of 211Astatine-Conjugated Anti-CD45 Antibody-Based Conditioning for Hematopoietic Stem Cell Gene Therapy and Editing$861,939
R01 · FY2023 · HL
Nongenotoxic conditioning for gene therapy and allogeneic transplantation in Fanconi anemia$811,794
R01 · FY2023 · HL · contact PI
Multiplex base/prime editors for in vivo selection of modified HSPCs in hemoglobinopathy$767,986
R01 · FY2023 · HL · contact PI
In vivo HSC gene therapy using a multi-modular HDAd vector for HIV cure$685,904
R01 · FY2023 · AI
Nongenotoxic conditioning to enhance stem cell engineering and virus-specific immunity in nonhuman primates$518,177
U19 · FY2023 · HL · contact PI
Cell Manipulation Tools$225,250
U54 · FY2023 · DK · contact PI
Modeling HIV CAR-T cell trafficking and persistence in Non-Human Primates$120,227
U19 · FY2023 · AI · contact PI
Novel hematopoietic stem cell engineering and transplantation approaches for HIV cure$2,978,475
U19 · FY2022 · HL
Nonhuman Primate Core$906,156
U19 · FY2022 · AI · contact PI
Development of 211Astatine-Conjugated Anti-CD45 Antibody-Based Conditioning for Hematopoietic Stem Cell Gene Therapy and Editing$869,409
R01 · FY2022 · HL
Nongenotoxic conditioning for gene therapy and allogeneic transplantation in Fanconi anemia$751,370
R01 · FY2022 · HL · contact PI
Modeling HIV CAR-T cell trafficking and persistence in Non-Human Primates$740,614
U19 · FY2022 · AI · contact PI
Multiplex base/prime editors for in vivo selection of modified HSPCs in hemoglobinopathy$721,635
R01 · FY2022 · HL · contact PI
Primate Core$698,006
U19 · FY2022 · HL · contact PI
Targeting a Novel Hematopoietic Stem Cell Population in Non-Human Primates for Effective and Sustained Gene Therapy$684,721
R01 · FY2022 · AI · contact PI
Endothelial cell transplantation for multi-organ repair to counter radiation injury$586,384
U01 · FY2022 · AI
Nongenotoxic conditioning to enhance stem cell engineering and virus-specific immunity in nonhuman primates$498,553
U19 · FY2022 · HL · contact PI
Cell Manipulation Tools$225,250
U54 · FY2022 · DK · contact PI
Targeting a Novel Hematopoietic Stem Cell Population in Non-Human Primates for Effective and Sustained Gene Therapy$205,877
R01 · FY2022 · AI · contact PI
Nongenotoxic conditioning for gene therapy and allogeneic transplantation in Fanconi anemia$67,480
R01 · FY2022 · HL · contact PI
Multiplex base/prime editors for in vivo selection of modified HSPCs in hemoglobinopathy$63,432
R01 · FY2022 · HL · contact PI
Novel hematopoietic stem cell engineering and transplantation approaches for HIV cure$2,658,178
U19 · FY2021 · HL
Modeling HIV CAR-T cell trafficking and persistence in Non-Human Primates$968,416
U19 · FY2021 · AI · contact PI
Nonhuman Primate Core$897,927
U19 · FY2021 · AI · contact PI
Targeting a Novel Hematopoietic Stem Cell Population in Non-Human Primates for Effective and Sustained Gene Therapy$890,598
R01 · FY2021 · AI · contact PI
Development of 211Astatine-Conjugated Anti-CD45 Antibody-Based Conditioning for Hematopoietic Stem Cell Gene Therapy and Editing$877,086
R01 · FY2021 · HL
Nongenotoxic conditioning for gene therapy and allogeneic transplantation in Fanconi anemia$823,789
R01 · FY2021 · HL · contact PI
Endothelial cell transplantation for multi-organ repair to counter radiation injury$794,401
U01 · FY2021 · AI
Multiplex base/prime editors for in vivo selection of modified HSPCs in hemoglobinopathy$747,027
R01 · FY2021 · HL · contact PI
Nongenotoxic conditioning to enhance stem cell engineering and virus-specific immunity in nonhuman primates$592,767
U19 · FY2021 · HL · contact PI
Primate Core$507,096
U19 · FY2021 · HL · contact PI
Cell Manipulation Tools$151,223
U54 · FY2021 · DK · contact PI
Cell Manipulation Tools$74,015
U54 · FY2021 · DK · contact PI
Development of 211Astatine-Conjugated Anti-CD45 Antibody-Based Conditioning for Hematopoietic Stem Cell Gene Therapy and Editing$1
R01 · FY2021 · HL
Cell and Gene Therapy for HIV Cure$4,564,019
UM1 · FY2020 · AI
Novel hematopoietic stem cell engineering and transplantation approaches for HIV cure$3,085,105
U19 · FY2020 · HL
Modeling HIV CAR-T cell trafficking and persistence in Non-Human Primates$996,038
U19 · FY2020 · AI · contact PI
Nonhuman Primate Core$922,207
U19 · FY2020 · AI · contact PI
Novel Gene Editing Approaches for Hemoglobinopathies$921,786
R01 · FY2020 · HL · contact PI
Targeting a Novel Hematopoietic Stem Cell Population in Non-Human Primates for Effective and Sustained Gene Therapy$890,598
R01 · FY2020 · AI · contact PI
Development of 211Astatine-Conjugated Anti-CD45 Antibody-Based Conditioning for Hematopoietic Stem Cell Gene Therapy and Editing$881,880
R01 · FY2020 · HL
Nongenotoxic conditioning for gene therapy and allogeneic transplantation in Fanconi anemia$849,490
R01 · FY2020 · HL · contact PI
Endothelial cell transplantation for multi-organ repair to counter radiation injury$598,836
U01 · FY2020 · AI
Primate Core$514,184
U19 · FY2020 · AI · contact PI
Nongenotoxic conditioning to enhance stem cell engineering and virus-specific immunity in nonhuman primates$514,184
U19 · FY2020 · AI · contact PI
Dendritic Cell Vaccine for Controlling the Latent Reservoir$504,970
R33 · FY2020 · AI
Cell and Gene Therapy for HIV Cure$407,345
UM1 · FY2020 · AI
Cell and Gene Therapy for HIV Cure$5,044,836
UM1 · FY2019 · AI
Next Generation HSC Gene Therapy for HIV Control and Eradication$2,529,095
U19 · FY2019 · HL
Cell and Gene Therapy for Nonmalignant Blood Disorders$2,423,242
P01 · FY2019 · HL · contact PI
Novel Gene Editing Approaches for Hemoglobinopathies$921,786
R01 · FY2019 · HL · contact PI
Targeting a Novel Hematopoietic Stem Cell Population in Non-Human Primates for Effective and Sustained Gene Therapy$890,598
R01 · FY2019 · AI · contact PI
Endothelial cell transplantation for multi-organ repair to counter radiation injury$706,493
U01 · FY2019 · AI
Project 3: Gene Therapy for Correction of Blood Disorders$604,529
P01 · FY2019 · HL · contact PI
Stem cell expansion and gene editing in a nonhuman primate model of HIV/AIDS$530,022
U19 · FY2019 · HL · contact PI
Dendritic Cell Vaccine for Controlling the Latent Reservoir$506,210
R33 · FY2019 · AI
Cell and Gene Therapy for Nonmalignant Blood Disorders$109,674
P01 · FY2019 · HL · contact PI
Cell and Gene Therapy for HIV Cure$4,714,991
UM1 · FY2018 · AI
Cell and Gene Therapy for Nonmalignant Blood Disorders$2,554,007
P01 · FY2018 · HL · contact PI
Next Generation HSC Gene Therapy for HIV Control and Eradication$2,529,095
U19 · FY2018 · HL
Novel Gene Editing Approaches for Hemoglobinopathies$921,786
R01 · FY2018 · HL · contact PI
Targeting a Novel Hematopoietic Stem Cell Population in Non-Human Primates for Effective and Sustained Gene Therapy$909,598
R01 · FY2018 · AI · contact PI
Endothelial cell transplantation for multi-organ repair to counter radiation injury$647,025
U01 · FY2018 · AI
Project 3: Gene Therapy for Correction of Blood Disorders$607,654
P01 · FY2018 · HL · contact PI
Dendritic Cell Vaccine for Controlling the Latent Reservoir$541,762
R33 · FY2018 · AI
Stem cell expansion and gene editing in a nonhuman primate model of HIV/AIDS$530,022
U19 · FY2018 · HL · contact PI
Cell and Gene Therapy for HIV Cure$4,714,991
UM1 · FY2017 · AI
Next Generation HSC Gene Therapy for HIV Control and Eradication$2,514,507
U19 · FY2017 · HL
Novel Gene Editing Approaches for Hemoglobinopathies$959,786
R01 · FY2017 · HL · contact PI
Project 3: Gene Therapy for Correction of Blood Disorders$611,660
P01 · FY2017 · HL · contact PI
Stem cell expansion and gene editing in a nonhuman primate model of HIV/AIDS$530,022
U19 · FY2017 · HL · contact PI
Engraftment and in vivo selection of HIV-protected stem cells$523,418
R01 · FY2017 · HL · contact PI
Dendritic Cell Vaccine for Controlling the Latent Reservoir$217,685
R21 · FY2017 · AI
2017 Conference on Cell and Gene Therapy for HIV CURE$25,000
R13 · FY2017 · AI
Cell and Gene Therapy for HIV Cure$4,714,991
UM1 · FY2016 · AI
Next Generation HSC Gene Therapy for HIV Control and Eradication$2,514,507
U19 · FY2016 · HL
Foamy Viral Gene Therapy for X-linked Severe Combined Immune Deficiency$2,468,421
P01 · FY2016 · AI
Evaluation of Pluripotent Stem Cell-Derived Blood Cells in Nonhuman Primate Model$835,271
R01 · FY2016 · HL · contact PI
Engraftment and in vivo selection of HIV-protected stem cells$808,300
R01 · FY2016 · HL · contact PI
Foamy Virus Mediated gene Therapy in the Canine SCID-X1 model$732,752
P01 · FY2016 · AI · contact PI
Project 3: Gene Therapy for Correction of Blood Disorders$613,758
P01 · FY2016 · HL · contact PI
Vector Production$546,738
P01 · FY2016 · AI · contact PI
Stem cell expansion and gene editing in a nonhuman primate model of HIV/AIDS$530,022
U19 · FY2016 · HL · contact PI
Dendritic Cell Vaccine for Controlling the Latent Reservoir$239,781
R21 · FY2016 · AI
Targeted Modification of Host and Proviral DNA to Treat Latent HIV Infection$4,371,340
U19 · FY2015 · AI
Next Generation HSC Gene Therapy for HIV Control and Eradication$2,516,838
U19 · FY2015 · HL
Foamy Viral Gene Therapy for X-linked Severe Combined Immune Deficiency$2,468,981
P01 · FY2015 · AI
Evaluation of Pluripotent Stem Cell-Derived Blood Cells in Nonhuman Primate Model$825,114
R01 · FY2015 · HL · contact PI
Engraftment and in vivo selection of HIV-protected stem cells$792,237
R01 · FY2015 · HL · contact PI
Foamy Virus Mediated gene Therapy in the Canine SCID-X1 model$733,318
P01 · FY2015 · AI · contact PI
Project 3: Gene Therapy for Correction of Blood Disorders$618,189
P01 · FY2015 · HL · contact PI
Transplantation Core$596,571
U19 · FY2015 · AI · contact PI
Vector Production$547,155
P01 · FY2015 · AI · contact PI
Stem cell expansion and gene editing in a nonhuman primate model of HIV/AIDS$546,229
U19 · FY2015 · HL · contact PI
CCR5 Targeting to Control HIV/SHIV to Nonhuman Primates$520,756
U19 · FY2015 · AI · contact PI
Next Generation HSC Gene Therapy for HIV Control and Eradication$228,390
U19 · FY2015 · HL
Cell-Based Secretion of Antiviral Molecules as a Treatment for HIV-AIDS$222,367
R21 · FY2015 · AI · contact PI
Targeted Modification of Host and Proviral DNA to Treat Latent HIV Infection$4,068,789
U19 · FY2014 · AI
Foamy Viral Gene Therapy for X-linked Severe Combined Immune Deficiency$2,472,869
P01 · FY2014 · AI
Evaluation of Pluripotent Stem Cell-Derived Blood Cells in Nonhuman Primate Model$841,579
R01 · FY2014 · HL · contact PI
Transplantation Core$628,430
U19 · FY2014 · AI · contact PI
Foamy Virus Mediated gene Therapy in the Canine SCID-X1 model$573,322
P01 · FY2014 · AI · contact PI
Vector Production$465,065
P01 · FY2014 · AI · contact PI
Cell-Based Secretion of Antiviral Molecules as a Treatment for HIV-AIDS$259,621
R21 · FY2014 · AI · contact PI
CCR5 Targeting to Control HIV/SHIV to Nonhuman Primates$248,918
U19 · FY2014 · AI · contact PI
Core D: Vector Production$177,106
P30 · FY2014 · DK · contact PI
Targeted Modification of Host and Proviral DNA to Treat Latent HIV Infection$4,375,129
U19 · FY2013 · AI
Foamy Viral Gene Therapy for X-linked Severe Combined Immune Deficiency$2,089,212
P01 · FY2013 · AI
Evaluation of Pluripotent Stem Cell-Derived Blood Cells in Nonhuman Primate Model$823,092
R01 · FY2013 · HL · contact PI
Engraftment and in vivo selection of HIV-protected stem cells$769,503
R01 · FY2013 · HL · contact PI
Development of safe and efficient gene therapy strategies for hemoglobinopathies$669,194
R01 · FY2013 · HL · contact PI
Transplantation Core$641,192
U19 · FY2013 · AI · contact PI
Foamy Virus Mediated gene Therapy in the Canine SCID-X1 model$587,209
P01 · FY2013 · AI · contact PI
Vector Production$310,898
P01 · FY2013 · AI · contact PI
CCR5 Targeting to Control HIV/SHIV to Nonhuman Primates$247,916
U19 · FY2013 · AI · contact PI
Core D: Vector Production$173,563
P30 · FY2013 · DK · contact PI
Targeted Modification of Host and Proviral DNA to Treat Latent HIV Infection$4,033,771
U19 · FY2012 · AI
Foamy Viral Gene Therapy for X-linked Severe Combined Immune Deficiency$2,385,885
P01 · FY2012 · AI
Engraftment and in vivo selection of HIV-protected stem cells$876,137
R01 · FY2012 · HL · contact PI
Development of safe and efficient gene therapy strategies for hemoglobinopathies$704,283
R01 · FY2012 · HL · contact PI
Foamy Virus Mediated gene Therapy in the Canine SCID-X1 model$666,184
P01 · FY2012 · AI · contact PI
Transplantation Core$580,583
U19 · FY2012 · AI · contact PI
Development of Novel AIDS Gene Therapy Strategies in the Macaque SHIV Model$564,464
R01 · FY2012 · AI · contact PI
CCR5 Targeting to Control HIV/SHIV to Nonhuman Primates$556,001
U19 · FY2012 · AI · contact PI
Vector Production$360,553
P01 · FY2012 · AI · contact PI
Testing of novel system to deliver VRC01 in mouse model$300,000
R41 · FY2012 · AI
Core D: Vector Production$182,920
P30 · FY2012 · DK · contact PI
Targeted Modification of Host and Proviral DNA to Treat Latent HIV Infection$3,932,050
U19 · FY2011 · AI
Transplantation Core$715,823
U19 · FY2011 · AI · contact PI
Development of safe and efficient gene therapy strategies for hemoglobinopathies$704,921
R01 · FY2011 · HL · contact PI
LAGLIDADG Delivery and Gene Repair in Hematopoietic Stem Cells (7 of 11)$607,698
RL1 · FY2011 · HL · contact PI
Development of Novel AIDS Gene Therapy Strategies in the Macaque SHIV Model$551,896
R01 · FY2011 · AI · contact PI
Hematopoietic Chemoprotection in Glioblastoma Patients$439,580
R01 · FY2011 · CA · contact PI
CCR5 Targeting to Control HIV/SHIV to Nonhuman Primates$276,808
U19 · FY2011 · AI · contact PI
Gene Therapy in Hematopoietic Cells$777,107
P01 · FY2010 · HL · contact PI
Development of safe and efficient gene therapy strategies for hemoglobinopathies$735,238
R01 · FY2010 · HL · contact PI
LAGLIDADG Delivery and Gene Repair in Hematopoietic Stem Cells (7 of 11)$610,912
RL1 · FY2010 · HL · contact PI
Development of Novel AIDS Gene Therapy Strategies in the Macaque SHIV Model$524,469
R01 · FY2010 · AI · contact PI
Hematopoietic Chemoprotection in Glioblastoma Patients$445,303
R01 · FY2010 · CA · contact PI
Core D: Vector Production$180,442
P30 · FY2010 · DK · contact PI
Development of Novel AIDS Gene Therapy Strategies in the Macaque SHIV Model$13,265
R01 · FY2010 · AI · contact PI
Cord Blood Expansion and Transplantation in a Nonhuman Primate Model$729,751
R01 · FY2009 · HL · contact PI
Gene Therapy in Hematopoietic Cells$710,951
P01 · FY2009 · HL · contact PI
Gene therapy for Fanconi anemia$669,918
R01 · FY2009 · HL · contact PI
LAGLIDADG Delivery and Gene Repair in Canine Hematopoietic Stem Cells (7 of 11)$601,605
RL1 · FY2009 · HL · contact PI
Development of Novel AIDS Gene Therapy Strategies in the Macaque SHIV Model$557,902
R01 · FY2009 · AI · contact PI
LAGLIDADG Delivery and Gene Repair in Canine Hematopoietic Stem Cells (7 of 11)$98,968
RL1 · FY2009 · HL · contact PI
Cord Blood Expansion and Transplantation in a Nonhuman Primate Model$696,505
R01 · FY2008 · HL · contact PI
Gene therapy for Fanconi anemia$638,503
R01 · FY2008 · HL · contact PI
Gene Therapy in Hematopoietic Cells$635,565
P01 · FY2008 · HL · contact PI
LAGLIDADG Delivery and Gene Repair in Canine Hematopoietic Stem Cells (7 of 11)$586,585
RL1 · FY2008 · HL · contact PI
Hematopoietic Chemoprotection in Glioblastoma Patients$443,776
R01 · FY2008 · CA · contact PI
Gene Transfer into Hematopoietic Stem Cells$408,564
P01 · FY2008 · HL · contact PI
CORE--LARGE ANIMAL$145,972
P01 · FY2008 · HL · contact PI
Core--Hematopoietic Cell Transduction$134,931
P30 · FY2008 · DK · contact PI
Cord Blood Expansion and Transplantation in a Nonhuman Primate Model$692,238
R01 · FY2007 · HL · contact PI
Gene therapy for Fanconi anemia$633,686
R01 · FY2007 · HL · contact PI
Gene Therapy in Hematopoietic Cells$625,642
P01 · FY2007 · HL · contact PI
LAGLIDADG Delivery and Gene Repair in Canine Hematopoietic Stem Cells$572,000
RL1 · FY2007 · HL · contact PI
Safety and Efficacy of AIDS Gene Therapy in Monkeys$482,696
P01 · FY2007 · AI · contact PI
Hematopoietic Chemoprotection in Glioblastoma Patients$441,631
R01 · FY2007 · CA · contact PI
Gene Transfer into Hematopoietic Stem Cells$307,516
P01 · FY2007 · HL · contact PI
CORE--LARGE ANIMAL$169,321
P01 · FY2007 · HL · contact PI
Core--Hematopoietic Cell Transduction$124,621
P30 · FY2007 · DK · contact PI
Cord Blood Expansion/Transplantation Nonhuman Primate$712,684
R01 · FY2006 · HL · contact PI
Gene therapy for Fanconi anemia$651,446
R01 · FY2006 · HL · contact PI
Gene Therapy in Hematopoietic Cells$561,728
P01 · FY2006 · HL · contact PI
Safety and Efficacy of AIDS Gene Therapy in Monkeys$494,958
P01 · FY2006 · AI · contact PI
Hematopoietic Chemoprotection in Glioblastoma Patients$461,965
R01 · FY2006 · CA · contact PI
MGMT-Mediated in vivo Selection in a Large Animal Model$422,336
R01 · FY2006 · HL · contact PI
Gene Transfer into Hematopoietic Stem Cells$300,286
P01 · FY2006 · HL · contact PI
CORE--LARGE ANIMAL$162,439
P01 · FY2006 · HL · contact PI
Core--Hematopoietic Cell Transduction$132,968
P30 · FY2006 · DK · contact PI
Suplement to Safety and Efficacy of AIDS Gene Therapy in Monkeys$75,000
P01 · FY2006 · AI · contact PI
Safety and Efficacy of AIDS Gene Therapy in Monkeys$476,545
P01 · FY2005 · AI
MGMT-Mediated in vivo Selection in a Large Animal Model$432,500
R01 · FY2005 · HL
Gene Therapy for Patients with Fanconi Anemia$322,667
U01 · FY2005 · HL
Gene Transfer into Hematopoietic Stem Cells$291,538
P01 · FY2005 · HL
GENE THERAPY IN HEMATOPOIETIC CELLS$194,994
P01 · FY2005 · HL
CORE--LARGE ANIMAL$157,709
P01 · FY2005 · HL
Core--Hematopoietic Cell Transduction$132,968
P30 · FY2005 · DK
Safety and Efficacy of AIDS Gene Therapy in Monkeys$475,678
P01 · FY2004 · AI
MGMT-Mediated in vivo Selection in a Large Animal Model$432,500
R01 · FY2004 · HL
Gene Transfer into Hematopoietic Stem Cells$295,947
P01 · FY2004 · HL
GENE THERAPY IN HEMATOPOIETIC CELLS$189,314
P01 · FY2004 · HL